Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar i Disorder

Robert L Findling, Ronald L. Landbloom, Armin Szegedi, Janelle Koppenhaver, Sabine Braat, Qi Zhu, Mary Mackle, Kiki Chang, Maju Mathews

Research output: Contribution to journalArticle

Abstract

Objective To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes. Method In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary efficacy measure was change from baseline in Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of patients with/without attention-deficit/hyperactivity disorder (ADHD) and with/without stimulant use were performed. Results The mean difference in asenapine versus placebo in YMRS was -3.2 (p =.0008), -5.3 (p

Original languageEnglish (US)
Pages (from-to)1032-1041
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume54
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Bipolar Disorder
Placebos
Pediatrics
Therapeutics
Attention Deficit Disorder with Hyperactivity
Double-Blind Method
Asenapine

Keywords

  • asenapine
  • bipolar I disorder
  • manic episode
  • mixed episode

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar i Disorder. / Findling, Robert L; Landbloom, Ronald L.; Szegedi, Armin; Koppenhaver, Janelle; Braat, Sabine; Zhu, Qi; Mackle, Mary; Chang, Kiki; Mathews, Maju.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 54, No. 12, 2015, p. 1032-1041.

Research output: Contribution to journalArticle

Findling, Robert L ; Landbloom, Ronald L. ; Szegedi, Armin ; Koppenhaver, Janelle ; Braat, Sabine ; Zhu, Qi ; Mackle, Mary ; Chang, Kiki ; Mathews, Maju. / Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar i Disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2015 ; Vol. 54, No. 12. pp. 1032-1041.
@article{2117863c13af4225bf473a8f43b23756,
title = "Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar i Disorder",
abstract = "Objective To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes. Method In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary efficacy measure was change from baseline in Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of patients with/without attention-deficit/hyperactivity disorder (ADHD) and with/without stimulant use were performed. Results The mean difference in asenapine versus placebo in YMRS was -3.2 (p =.0008), -5.3 (p",
keywords = "asenapine, bipolar I disorder, manic episode, mixed episode",
author = "Findling, {Robert L} and Landbloom, {Ronald L.} and Armin Szegedi and Janelle Koppenhaver and Sabine Braat and Qi Zhu and Mary Mackle and Kiki Chang and Maju Mathews",
year = "2015",
doi = "10.1016/j.jaac.2015.09.007",
language = "English (US)",
volume = "54",
pages = "1032--1041",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar i Disorder

AU - Findling, Robert L

AU - Landbloom, Ronald L.

AU - Szegedi, Armin

AU - Koppenhaver, Janelle

AU - Braat, Sabine

AU - Zhu, Qi

AU - Mackle, Mary

AU - Chang, Kiki

AU - Mathews, Maju

PY - 2015

Y1 - 2015

N2 - Objective To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes. Method In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary efficacy measure was change from baseline in Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of patients with/without attention-deficit/hyperactivity disorder (ADHD) and with/without stimulant use were performed. Results The mean difference in asenapine versus placebo in YMRS was -3.2 (p =.0008), -5.3 (p

AB - Objective To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes. Method In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary efficacy measure was change from baseline in Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of patients with/without attention-deficit/hyperactivity disorder (ADHD) and with/without stimulant use were performed. Results The mean difference in asenapine versus placebo in YMRS was -3.2 (p =.0008), -5.3 (p

KW - asenapine

KW - bipolar I disorder

KW - manic episode

KW - mixed episode

UR - http://www.scopus.com/inward/record.url?scp=84961675273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961675273&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2015.09.007

DO - 10.1016/j.jaac.2015.09.007

M3 - Article

C2 - 26598478

AN - SCOPUS:84961675273

VL - 54

SP - 1032

EP - 1041

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 12

ER -